Author | Miriam Tucker

Articles

Dapagliflozin Benefits Heart Failure Patients, With or Without Diabetes

October 09, 2019

The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.

Neither Linagliptin nor Glimepiride Increases Cardiovascular Risk in Diabetes

October 09, 2019

Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.

linagliptin Safe for Diabetes Patients with Elevated Cardiovascular Risk

October 02, 2019

Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.

Diabetes Drug Dapagliflozin Prevents Worsening Heart Failure, Study Shows

October 02, 2019

The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.